Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

• BTIG 13^th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT
  Participating on Tuesday, February 10, 2026
• TD Cowen 46^th Annual Health Care Conference in Boston, MA
  Fireside chat on Monday, March 2, 2026, at 11:50 a.m. Eastern Time

Interested parties may access live and archived webcasts of the session on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
[email protected]

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
[email protected]

You May Also Be Interested In

• Crypto Update: Pepeto Stage Sells Out at Record Speed While the Solana Price Prediction Targets $336 and Meme Coin Season Stars
• Truce Law Expands Family Law Services Across Western Washington
• Edesa Biotech Announces Pricing of $25.0 Million Public Offering